To determine whether men at risk of death from prostate cancer, despite radical prostatectomy, can be identified at diagnosis on the basis of PSA velocity. Pretreatment and follow-up data on ...

Using absolute prostate-specific antigen (PSA) thresholds to make decisions about diagnostic testing and biopsies remains controversial (Journal Watch Top Story Dec 31 2004), but PSA velocity (the ...

We need better ways to determine which prostate-specific antigen (PSA)-detected localized prostate cancers are most likely to progress. The rate at which the PSA level rises (i.e., PSA velocity) prior ...

We conducted a systematic review of studies published before March 2007 in which a PSA dynamic (velocity or doubling time) was calculated in patients before definitive treatment, a subsequent event ...

Elevated serum prostate-specific antigen (PSA) levels can indicate the presence of prostate cancer, although PSA levels are also elevated in some non-malignant conditions, which affects the ...

If you need further proof that medicine is just as much art as science, a new study shows that some common sense needs to prevail before rushing into possibly unnecessary prostate biopsies if there is ...

The most significant single predictor of aggressive prostate cancer is an elevated rate of increase in prostate specific antigen (PSA) levels, according to a new study. Published in the July 1, 2007 ...

Prostate biopsies based on PSA changes are largely unnecessary, researchers say. Feb. 25, 2010— -- If prostate biopsies were based only on the rate of change in PSA level over time, the number of ...

Some studies have suggested that the rate of change of prostate-specific antigen (PSA) levels may correspond with prostate cancer survival. But this does not necessarily mean that PSA velocity will be ...

An analysis of 5,519 men undergoing biopsy in the control arm of the Prostate Cancer Prevention Trial uncovered no evidence to support the recommendation that men with high PSA velocity be biopsied in ...

Radical prostatectomy (RP) patients who have a preoperative PSA velocity greater than 0.4 ng/mL per year are 50% less likely to have insignificant disease compared with patients with lower PSA ...